Ep. 597 Ablative Treatments & Radiotherapy: The Latest in Lung Cancer Treatment with Dr. Alan Lee, Dr. Scott Oh, and Dr. Rob Suh

Why might the standard RECIST criteria fail to accurately track success after tumor ablation, and what should you look for instead? In the 4th installment of the 2025 NSCLC Creator Weekend™ series, hosts Drs. Scott Genshaft and Kavi Krishnasamy are joined by specialists from UCLA and USC to discuss and debate advanced treatment options for primary lung cancer.

---

This podcast is supported by an educational grant from Johnson & Johnson and Varian.

---

SYNPOSIS

The panel, including interventional radiologists, pulmonologists, and a radiation oncologist, discusses the intricacies of photon versus proton therapies, the physics behind radiation treatment, and the evolving landscape of ablation technologies. The conversation covers the efficacy and limitations of different treatments, patient selection criteria, and the role of newer technologies like electroporation and robotic-assisted bronchoscopy in enhancing precision and outcomes. Additionally, the panel addresses the practical challenges of intraprocedural imaging, the importance of adequate margins, and the complexities of managing local recurrences and radiation-induced toxicities.

---

TIMESTAMPS

00:00 - Tumor Ablation and Recurrence Rates
12:53 - Advancements in Ablation Technologies
23:31 - Bronchoscopic Approaches in Lung Cancer Treatment
38:46 - Challenges in Radiation Dose and Delivery
49:21 - Ablation and Radiation Margins
01:07:19 - Final Thoughts

---

RESOURCES

Thierry de Baere Paper on Ablation Margins https://pmc.ncbi.nlm.nih.gov/articles/PMC9815739/